TBK1 and fatty liver disease: In contrast, Amlexanox is not only a non-specific GRK inhibitor but also a dual inhibitor of TBK1/IKKε, which reduces inflammation and inflammation-related insulin resistance, resulting in improved liver steatosis (24, 25).